|
FDA Panel to Vote on Approval, Dosing for COPD Drug
MedPage Today But, the "major safety issue with indacaterol is linked to selection of appropriate dose, because beta-adrenergic agonist bronchodilators, particularly at high doses, have the safety concern of severe asthma exacerbations and asthma related deaths in … |
View full post on asthma – Google News